Endo to acquire Par for $8.05 billion
DUBLIN, Ireland — Endo International PLC plans to buy Par Pharmaceutical Holdings Inc. from TPG Capital North America in a deal valued at $8.05 billion. The pharmaceutical companies said Monday that the combination will create a leading specialty pharmaceutical company with a generics business that is one of the industry’s fastest-growing and among the top five by U.S.
